Buzz for ALK-Abell� as NICE says yes to Pharmalgen
This article was originally published in Scrip
NICE, the health technology appraisal institute for England and Wales, has published final guidance recommending ALK-Abell�'s Pharmalgen as a treatment for bee and wasp venom allergy.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.